Drugs company Cerecor raises $6.8m from private backers for depression treatment.

Biopharamaceutical firm Cerecor has raised $6.8m in series A funding to support development of its neuroscience drugs. The US-based company is licensing and commercialising small molecule D-Amino Acid Oxidase (DAAO) inhibitors which were originally developed at the Johns Hopkins Brain Science Institute. In addition, Cerecor is transferring depression treatment, CERC-301, from life sciences firm Merck.…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.